Mesothelioma Sample Clauses

Mesothelioma. The review focused on:
Sample 1
AutoNDA by SimpleDocs
Mesothelioma. The revision had a negligible impact on incidence (Table 12) of mesothelioma however it had an interesting impact on survival (Table 13). Table 12. Malignant mesothelioma crude incidence rate before and after the revision No cases incidence rate Lower 95%CI Upper 95%CI before revision MALIGNANT MESOTHELIOMA 4,229 1.4 1.4 1.5 Mesothelioma of the pleura and pericardium 3,764 1.3 1.2 1.3 Mesothelioma of the peritoneum tunica vaginalis 355 0.1 0.1 0.1 after revision MALIGNANT MESOTHELIOMA 4,268 1.5 1.4 1.5 Mesothelioma of the pleura and pericardium 3,807 1.3 1.3 1.3 Mesothelioma of the peritoneum tunica vaginalis 352 0 0.1 0.1 Table 13. Malignant mesothelioma 1 and 5-year relative survival before and after the revision 1 year 5-year No of cases relative survival % Lower 95% CI Upper 95% CI No of cases relative survival % Lower 95% CI Upper 95% CI MALIGNANT MESOTHELIOMA 2,702 39.5 37.6 41.4 2702 7.2 6.2 8.4 before revision Mesothelioma of the pleura and pericardium 2,421 40.2 38.1 42.2 2421 6.1 5.1 7.3 Mesothelioma of the peritoneum tunica vaginalis 225 31.6 25.5 37.9 225 13.9 9.4 19.3 MALIGNANT MESOTHELIOMA 2,715 37.7 35.9 39.6 2715 5.5 4.6 6. 6 after revision Mesothelioma of the pleura and pericardium 2,441 38.4 36.4 40.4 2441 4.6 3.7 5.5 Mesothelioma of the peritoneum tunica vaginalis 221 29.4 23.41 35.6 221 12.6 8.3 17.9 Even if 85% were confirmed mesothelioma long survivors, 5-year survival in the sample of CRs studied, decreased from 7.2% before the revision to 5.5% after the revision. Inferring/expanding the results of the revision to the entire database of RARECARE is possible to understand what kind of impact a correction of misclassified cases would have on the mesothelioma survival estimates. We assume 2 scenarios:
Sample 1
Mesothelioma. The review will focus on long term survivors with ICD-O morphology 9050-9053 of any sites and of all cases with pleural cancers that are not coded as mesothelioma. For this lethal cancer, we expect a very low proportion of cases alive two or more years after diagnosis thus, all the incident cases diagnosed during the study period, alive two (or three) years after the diagnosis have to be checked. For these cases the revision should: confirm the diagnosis, this may be the case for patients surgically treated, or for patients that have undergone multimodal treatment (surgery, plus chemo/radiotherapy) or change the diagnosis specifying the new code if it was a non malignant lesion of the pleura. Actually, pulmonary pleura in asbestos exposed people could be site of nodules, inflammatory pseudo-tumour, atypical adenomatous hyperplasia, etc. Furthermore, the pleura could be site of distant metastasis. and correct the life status of the patient because the death certificate was not correctly linked. In order to ascertain the completeness of mesothelioma of the pleura, all the pleura non mesothelioma cases have to be checked. LIVER ANGIOSARCOMA To identify missing cases, the revision will focus on all liver cancers (topography ICD10 C22.0) microscopically verified and with a morphologic code different from: 8160 (cholangiocarcinoma), 8161 (cystadenocarcinoma), 8170 (hepatocellular carcinoma), 8171 (fibrolamellar hepatocellular carcinoma), 8180 (hepato-cholangioma), 9590, 9591 (lymphoma), 8970 (hepatoblastoma), The above listed cancers are the most frequent usual primary liver cancers and so, with a high degree of probability to be well coded in the database. The quality of diagnosis and the completeness of incidence will be checked also through the revision of all sarcoma (not otherwise specified) NOS of the liver (only microscopically verified cases). For these cases the revision should confirm the diagnosis or change the diagnosis reporting the new code. In addition for angiosarcoma long term survivors the life status and the date of end of follow up have to be checked.
Sample 1
Mesothelioma. In order for an Asbestos Claimant to qualify for compensation under the Master Settlement Agreement as a Mesothelioma Asbestos Claim, the Asbestos Claimant must submit a report by a Board-certified Pathologist that the Asbestos Claimant has a diagnosis of a malignant mesothelioma. In addition, the documentation submitted must establish a 10-year latency period between the date of the first exposure of the Asbestos Claimant to asbestos and the date of diagnosis of mesothelioma. A Death Certificate alone cannot serve as medical documentation supporting an Asbestos Claim for mesothelioma.
Sample 1

Related to Mesothelioma

  • Field The term “

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Medi Cal PII is information directly obtained in the course of performing an administrative function on behalf of Medi-Cal, such as determining Medi-Cal eligibility or conducting IHSS operations, that can be used alone, or in conjunction with any other information, to identify a specific individual. PII includes any information that can be used to search for or identify individuals, or can be used to access their files, such as name, social security number, date of birth, driver’s license number or identification number. PII may be electronic or paper. AGREEMENTS

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Medical Inquiries Promptly after the Registrations have been transferred to Buyer, Buyer shall assume all responsibility for all correspondence and communication with physicians and other health care professionals and customers in the applicable Territory relating to the CV Products. After the Closing Date, Buyer and Seller shall work together towards an orderly transition of the responsibility for all correspondence and communication with health care professionals and customers in the applicable Territory relating to the CV Products. Seller shall continue to be responsible for such correspondence and communication under the direction of Buyer until the Registrations have been transferred to Buyer. Buyer shall keep such records and make such reports as shall be reasonably necessary to document such communications in compliance with all applicable regulatory requirements. After transfer of responsibility to Buyer pursuant to this Article 10, Seller shall, except in the case of medical emergency, refer all questions relating to the CV Products raised by health care professionals and customers to Buyer for its response.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!